In patients with atherosclerotic cardiovascular disease, inclisiran provides effective LDL cholesterol lowering with a ...
ATLANTA, GA—Using inclisiran (Leqvio; Novartis) as soon as possible in the care of patients with atherosclerotic cardiovascular disease (ASCVD) is associated with sustained lowering of LDL cholesterol ...
Dr James Chambers discusses handling a patient enquiry about inclisiran, including how to explain current evidence for its ...
Dr Naveen Bhamri explained 'game changer' injectable treatments to manage high cholesterol for patients who do not respond ...
The update removes the requirement for Leqvio to be used as an adjunct to statin therapy. The Food and Drug Administration (FDA) has approved a labeling update for Leqvio ® (inclisiran) allowing for ...
WASHINGTON, DC — Treatment with inclisiran (Alnylam Pharmaceuticals/the Medicines Company), which suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis in the liver, can ...
Please provide your email address to receive an email when new articles are posted on . “The PCSK9 inhibitors have all been given by injection, every 2 to 4 weeks for the fully human monoclonal ...
More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when ...
Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A doctor or healthcare professional will administer the medication as an injection under the skin. Original ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results